SVP™ for Immune Stimulation

Synthetic Vaccine Particles (SVP™) can contain encapsulated and/or surface antigens, as well as toll-like receptor (TLR) agonist adjuvants to activate immune responses, such as an antibody response to a target antigen, a cytolytic T cell response, or both.

The encapsulation of TLR agonists (SVP-TLR) has the potential to prevent dose limiting reactions that can be associated with freely delivered TLR agonists. Together with a disease-specific antigen, SVP are designed to induce targeted antigen-specific immune stimulation.

Back to Top